Health Care • Biotechnology: Pharmaceutical Preparations
$129.53 ▼ -10.16
(-7.27%)
MKT CAP: $5.84B • VOL: 636.8K
52W L $32 52W H $147
MANE // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 |
|---|---|---|
| Revenue (Total Sales) | $202.6M | $75.0M |
| YoY Revenue Growth % | — | — |
| Gross Profit | $0 | $0 |
| Gross Margin % | — | — |
| Research & Development (R&D) | — | — |
| Operating Income (EBIT) | -$72.3M | -$26.8M |
| Operating Margin % | — | — |
| Net Income (GAAP) | -$70.0M | -$26.5M |
| EBITDA (Normalized) | -$72.3M | -$26.8M |
| Diluted EPS ($/sh) | — | — |
| Operating Cash Flow (OCF) | -$71.6M | -$23.7M |
| Capital Expenditures (CapEx) | $24.0K | $0 |
| Free Cash Flow (FCF) | -$71.6M | -$23.7M |
| FCF Margin % | — | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% |
| Cash & Short-Term Equivalents | $21.8M | $53.1M |
| Total Debt (Short + Long Term) | $4.1M | $2.1M |
| Total Stockholders' Equity | -$121.0M | -$48.5M |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR MANE.